BL
BLTE
BLTE What Belite Bio promised, and what happened
Guidance
What management said, and what became of it
2 of 4 judged targets kept · 10 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Pediatric investigational plan initiation (Tinlarebant) | Initiate study | Dec 2025 | So we are initiating a PIP study, a pediatric study in London, where we will investigate Tinlarebant in patients of BH3311 and this will be the basis to inform regulatory processes for patients that are younger than 12 years old. | Delayed |
| Cash runway | about 4 years | Sep 2024 | we are extremely well funded into the future with a cash runway to commercialize Tinlarebant following a potential regulatory approval and to continue to advance our pipelines. | On Track |
The full ledger
Open Belite Bio’s full ledger
A free account opens 5 company ledgers a month. All 14 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 14 tracked commitments for Belite Bio
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.